目的 探討度他雄胺聯(lián)合坦索羅辛治療老年良性前列腺增生的臨床療效。方法 收集2013年1月—2014年1月新疆維吾爾自治區(qū)人民醫(yī)院收治的良性前列腺增生患者183例,隨機(jī)分為對(duì)照組(92例)和治療組(91例)。對(duì)照組口服鹽酸坦索羅辛緩釋膠囊1粒/次,1次/d。治療組口服度他雄胺軟膠囊,1粒/次,1次/d,同時(shí)口服鹽酸坦索羅辛緩釋膠囊,用法用量同對(duì)照組。兩組患者均連續(xù)治療24周。比較兩組的臨床療效,同時(shí)比較兩組治療前,治療8、16、24周最大尿流率(MFR)、殘余尿量(RU)、前列腺體積(PV)、泌尿癥狀困擾(BS)評(píng)分、國(guó)際前列腺癥狀(IPSS)評(píng)分的變化。結(jié)果 對(duì)照組和治療組總有效率分別為81.52%、90.11%,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P < 0.05)。治療后,兩組患者M(jìn)FR均較治療前顯著升高,RU、PV、BS評(píng)分、IPSS評(píng)分均較治療前顯著降低,同組治療前后差異有統(tǒng)計(jì)學(xué)意義(P < 0.05);且治療組這些指標(biāo)的改善程度優(yōu)于對(duì)照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P < 0.05)。結(jié)論 度他雄胺聯(lián)合坦索羅辛治療老年良性前列腺增生有較好的臨床療效,可以縮小前列腺體積和膀胱殘余尿量,改善患者下尿路癥狀,值得臨床推廣應(yīng)用。

objective To investigate the clinical effect of dutasteride combined with tamsulosin in treatment of elderly benign prostatic hyperplasia. Methods The patients with benign prostatic hyperplasia (183 cases) of the People's Hospital of Xinjiang Uygur Autonomous Region from January 2013 to January 2014 were randomly divided into control (n= 92) and treatment (n= 91) groups. The patients in the control group were po administered with Tamsulosin Hydrochloride Sustained Release Capsules, 1 grain/time, once daily. The patients in the treatment group were po administered with Dutasteride Soft Capsules, 1 grain/time, once daily, and the usage and dosage of Tamsulosin Hydrochloride Sustained Release Capsules were the same as the control group. The patients in two groups were treated for 24 weeks. After treatment, the efficacy was evaluated, and maximum urinary flow rate (MFR), residual urine (RU), prostatic volume (PV), boring score (BS), and international prostate symptom score (IPSS) before and 8, 16, 24 weeks after the treatment in two groups were compared. Results The efficacies in the control and treatment groups were 81.52% and 90.11%, respectively, and there were differences between two groups (P < 0.05). After treatment, MFR in two groups were significantly higher, while the RU, PV, BS, and IPSS score were significantly reduced, and the difference was statistically significant in the same group (P < 0.05). And these indicators in treatment group improved better than those in control group, with significant difference between two groups (P < 0.05). Conclusion Dutasteride combined with tamsulosin has the good clinical effect in treatment of elderly benign prostatic hyperplasia, and can reduce the prostate volume and bladder residual urine volume, while can improve lower urinary tract symptoms of patients, which is worth clinical promotion.